首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2008030

聚乙二醇化蛋白質市場：按類型、蛋白質類型、應用、最終用戶和地區分類

PEGylated Proteins Market, By Type, By Protein, By Application, By End User, By Geography

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年聚乙二醇化蛋白市場規模估計為22億美元，預計2033年將達47億美元。預計2026年至2033年，其複合年成長率將達11.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	22億美元
目標期限：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.60%	2033年市場規模預測：	47億美元

聚乙二醇化（PEGylation）是指透過添加活性聚乙二醇（PEG）對治療性蛋白質進行化學修飾的過程。這些經過化學修飾的治療性蛋白質稱為聚乙二醇化蛋白療法。聚乙二醇化蛋白療法用於治療多種疾病，包括癌症、血友病、類風濕性關節炎、僵直性脊椎炎類風濕性關節炎和克隆氏症。聚乙二醇化是指利用聚乙二醇（PEG，一種無毒性且無免疫抗原性的聚合物）對生物分子進行共價修飾，以彌補共用生物製藥的不足。

聚乙二醇（PEG）因其「無毒」和良好的生物相容性而被廣泛應用於藥物遞送和奈米技術領域。一般認為，PEG化能夠使生物材料和顆粒遞送系統逃避免疫系統的攻擊，並延長其循環壽命。然而，蛋白質的PEG化是一個複雜的過程，需要根據蛋白質類型和應用採用不同的方法。惰性PEG鏈透過共用或非共用鍵與標靶蛋白形成複合物。另一個關鍵步驟是PEG化蛋白的純化，這主要基於層析法、靜電相互作用或分子大小等因素。

市場動態

預計在預測期內，市場主要企業推出新產品等非內生策略的日益普及將推動市場成長。例如，2020年2月，諾和諾德在美國推出了ESPEROCT，用於治療A型血友病患者。 ESPEROCT是一種長效重組人類凝血因子VIII替代療法，用於預防或減少出血發作的頻率、治療和控制出血，以及管理A型血友病患者手術期間的出血。 ESPEROCT是一種抗血友病因子（重組）和糖基化-exei。

本次調查的主要特點。

本報告對全球聚乙二醇化蛋白市場進行了詳細分析，顯示了以 2025 年為基準年，預測期（2026-2033 年）的市場規模（以十億美元計）和復合年成長率（%）。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球聚乙二醇化蛋白市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過用於分析全球聚乙二醇化蛋白市場的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

Biogen Inc.
Pfizer Inc.
UCB SA
Leadiant Biosciences, Inc.
Amgen Inc.
Thermo Fisher Scientific Inc.
Horizon Therapeutics Plc.
Novo Nordisk A/S
F. Hoffmann-La Roche AG
Bayer AG
BioMarin
RedHill Biopharma Ltd

第10章

調查方法
關於本公司

簡介目錄

Product Code: CMI5354

PEGylated Proteins Market is estimated to be valued at USD 2.2 Bn in 2026 and is expected to reach USD 4.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.2 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.60%	2033 Value Projection:	USD 4.7 Bn

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals.

Due to its claimed silent qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei.

Key features of the study

This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PEGylated proteins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market

Market Segmentation

By Type
- Consumables
- Services
By Protein
- Colony-stimulating factor
- Interferons
- Erythropoietin
- Recombinant factor VII
- Other
By Application
- Cancer
- Autoimmune Disease
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorder
- Others
By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Biogen Inc
- Pfizer Inc
- UCB S.A.
- Leadiant Biosciences, Inc.
- Amgen Inc.
- Thermo Fisher Scientific Inc.
- Horizon Therapeutics Plc.
- Novo Nordisk A/S
- Hoffmann-La Roche AG
- Bayer AG
- BioMarin
- RedHill Biopharma Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Protein
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pipeline Analysis
PEST Analysis

4. Global PEGylated Proteins Market, By Type, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Consumables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
Services
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global PEGylated Proteins Market, By Protein, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Colony Stimulating Factor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
Interferon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Erythropoietin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Recombinant Factor VII
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global PEGylated Proteins Market, By Application, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Autoimmune Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Hepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Multiple Sclerosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Hemophilia
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Gastrointestinal Disorder
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global PEGylated Proteins Market, By End User, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Pharmaceutical and Biotechnology Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Contract Research Organizations
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Academic Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global PEGylated Proteins Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
UCB S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Leadiant Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Horizon Therapeutics Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BioMarin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
RedHill Biopharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies